<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453619</url>
  </required_header>
  <id_info>
    <org_study_id>APL2-201</org_study_id>
    <nct_id>NCT03453619</nct_id>
  </id_info>
  <brief_title>Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2
      subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients
      with glomerulopathies
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">October 22, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change From Baseline in Proteinuria at 16 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>IgA Nephropathy</condition>
  <condition>Lupus Nephritis</condition>
  <condition>Membranous Nephropathy</condition>
  <condition>C3 Glomerulonephritis</condition>
  <condition>Dense Deposit Disease</condition>
  <arm_group>
    <arm_group_label>APL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Label, Study Drug, APL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-2</intervention_name>
    <description>APL-2 is a C3 complement mediator administered as daily subcutaneous infusions</description>
    <arm_group_label>APL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Prior to screening, patients with at least 6 months of sufficient medical history will
        begin with a 4 week screening period, all other patients will enter the 12 week screening
        period.

        Medical History Inclusion Criteria:

        Documented at a minimum of 2 separate occasions over a duration no less than 6 months:

          -  Stable proteinuria &gt;1500 mg/day

          -  Average uACR &gt; 600 mg albumin/g creatinine

          -  Blood pressure &lt;140/90mm/Hg If applicable; stable dose of ACE/ARB for at least 6
             months prior to screening.

               1. Patients of at least 18 and less than 70 years of age at screening, able to
                  provide written informed consent, and able to understand and comply with all
                  scheduled procedures and other requirements of the study by the opinion of
                  Principal Investigator (PI)

               2. Patients must have a diagnosis of IgAN, LN, Primary MN, or C3G confirmed by renal
                  biopsy and required measurements performed prior to study participation

                    1. IgAN: Prior biopsy results for C3 and C4d staining should be made available

                    2. LN: Diagnostic biopsy showing proliferative focal or diffuse lesions (Class
                       III or IV) by renal biopsy with or without Class V (membranous) changes.
                       Subject should have either a repeat biopsy in the last 6 months, or evidence
                       of disease activity (nephritic changes on urinalysis or nephrotic changes)

                    3. Primary MN: PLA2R high titer plus nephrotic range proteinuria ( &gt;3.5 g
                       proteinuria/day)

                    4. C3G: Low serum C3 level and presence of C3 nephritic factor

               3. Have 24 hour proteinuria 1500 mg/day (determined by 24 hour urine collection) and
                  an average urine albumin/creatinine ratio &gt; 600 mg albumin/g creatinine
                  determined by spot urine samples collected consecutively during each visit during
                  the screening period (Visits 1/3a, 2, 3b) prior to 24 hour urine collection.

               4. If on immunosuppressive treatment (e.g. cyclophosphamide, mycophenolate mofetil,
                  calcineurin inhibitors, steroids), have been on a stable dose for at least 2
                  months prior to Screening Visit 1/3a with no expected change in the dose for the
                  study duration

               5. eGFR ≥ 30 mL/min/1.73 m2 calculated by CKD-EPI creatinine equation at screening
                  visit 1/3a

               6. Have a systolic blood pressure of &lt; 140 mmHg and a diastolic blood pressure of &lt;
                  90 mmHg at rest and if on physician-directed, stable, optimized treatment with
                  angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin receptor
                  blockers (ARB) have received treatment for at least 3 or 6 months prior to the
                  Screening Visit 1 or 3a, respectively.

               7. Willing to receive vaccinations against Neisseria meningitides at least 2 weeks
                  prior to dosing on Day 1 with a booster on Day 56 (for both vaccinations) and
                  Pneumococcal and Hib vaccines at least 2 weeks prior to dosing on Day 1, OR able
                  to provide documentary evidence of Neisseria meningitides types A, C, W, Y and B
                  (administered as two separate vaccinations), Pneumococcal conjugate vaccine or
                  Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and
                  Haemophilus influenza Type B (Hib) vaccination within 2 years prior to Day -14.

               8. Women of child-bearing potential (WOCBP) must have a negative blood pregnancy
                  test at screening and must agree to use protocol defined methods of contraception
                  from screening through 3 months after last dose of APL-2

               9. Males must agree to use protocol defined methods of contraception and agree to
                  refrain from donating sperm from screening through 3 months after receiving last
                  dose of APL-2

              10. Willing and able to give informed consent

              11. Willing and able to self-administer APL-2 (administration by caregiver will be
                  allowed)

        Exclusion Criteria:

          1. Hemoglobin &lt; 9.0 g/dL at screening Visits 1/3a and 3b

          2. Platelet count &lt; 100,000/mm3 at screening Visits 1/3a and 3b

          3. Absolute neutrophil count &lt; 500 cells/mm3 at screening Visits 1/3a and 3b

          4. ALT or AST &gt; 3.0 x the upper limit of normal at screening Visits 1/3a and 3b

          5. Use of belimumab, eculizumab, or rituximab within 6 months prior to Screening Visit
             1/3a

          6. Previous treatment with APL-2

          7. History of renal transplant

          8. Diagnosis of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
             infection, or positive serology at screening Visits 1/3a and 3b

          9. Any active infection requiring antibiotic treatment during the screening or treatment
             periods

         10. Malignancy except for cured basal or squamous cell skin cancer, curatively treated in
             situ disease or have been disease-free for ≥5 years or more from cancer

         11. Secondary IgA nephropathy: e.g. due to lupus, liver cirrhosis, IgA Vasculitis
             (Henoch-Schonlein purpura)

         12. Membranous Nephropathy secondary to another known disease

         13. Malignant/uncontrolled hypertension (&gt;160mm systolic or 110mmHg diastolic)

         14. Current unstable kidney function for other reasons, e.g. toxin induced acute kidney
             injury

         15. Presence or suspicion of active bacterial or viral infection or severe recurrent
             bacterial infections

         16. Participation in any other investigational drug trial or exposure to other
             investigational agent, device, or procedure within 30 days prior to screening period

         17. Pregnant, breast-feeding, or intending to conceive during the course of the study

         18. Inability to cooperate or any condition that, in the opinion of the investigator,
             could increase the patient's risk by participating in the study or confound the
             outcome of the study

         19. Unwillingness to receive or intolerant of SC injections of study medication or known
             allergy to ingredients in APL-2.

         20. Positive results for drug abuse (upon urinary drug screen) or alcohol dependence at
             screening (Visit 1/3a)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico Grossi, MD, PhD</last_name>
    <phone>617-977-5701</phone>
    <email>clinicaltrials@apellis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Investigational Site</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

